Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs iShares Semiconductor ETF (SOXX) Price & Performance

Inovio Pharmaceuticals IncTrade
iShares Semiconductor ETFTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs iShares Semiconductor ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while iShares Semiconductor ETF trades at $559.79 (market cap $48.19B). The key difference: iShares Semiconductor ETF is far larger — about 429.5× Inovio Pharmaceuticals Inc's market cap, and iShares Semiconductor ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and iShares Semiconductor ETF for 46 Days on average.

INOSOXX
Market Cap
$112.19M$48.19B
Volume
3,201,27810,257,578
Sector
HealthSector/Thematic
52-Week High
$2.65$655.01
52-Week Low
$0.66$268.10
Typical Hold Time
43 Days46 Days
Enterprise Value
$83.51M—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.

The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.

iShares Semiconductor ETF

SOXX trades at $559.67, down 3.99% on the day but maintains a bullish technical outlook with strong moving average signals. The semiconductor ETF benefits from AI-driven demand, with Bank of America projecting the global chip market could nearly double by 2030. Recent news highlights strong September performance and ongoing institutional interest, though Michael Burry's expanded short position signals some bearish sentiment.

The outlook remains positive given structural AI growth catalysts, but investors face valuation concerns with SOXX trading at a P/E premium versus broader markets. Key risks include concentration in top holdings and potential AI development slowdowns. Wall Street maintains generally bullish ratings based on earnings growth potential.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
96% Buy4% Sell
Avg holding period · 43 Days
SOXX
40% Buy60% Sell
Avg holding period · 46 Days

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About iShares Semiconductor ETF

SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.

Read more on SOXX →